Aurora Cannabis remains generally unprofitable on a full-year net income basis under GAAP accounting standards, frequently posting net losses driven by operational restructuring expenses, impairments, and excise taxes, despite achieving positive adjusted EBITDA milestones and growing international medical cannabis revenues. Management continues to focus on cost-efficiency measures, scaling EU-GMP production capacity in facilities like its Leuna plant in Germany, and expanding its global medical footprint to achieve sustainable long-term profitability.